Home / Letter From The Editor / June 16, 2020

June 16, 2020

Jun 16, 2020
 

We have spent a lot of time talking about TIR (Time in Range) for diabetes patients, but most of it is focused on type 1 patients. There is even more info on the long-term benefits of increased TIR being presented at this week’s ADA Virtual Scientific sessions.

But what about this idea for patients with type 2 diabetes? Can they benefit from less variability from month to month, and from office visit to office visit? This week our intern, Stephen Rubano, PharmD. Candidate, USF Taneja College of Pharmacy, looked back at the ACCORD trial and found there is a direct connection between Long Term A1c Stability and better outcomes.

 

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief